All In Biotech

NDA 209806 · Msd Sub Merck

Segluromet

Ertugliflozin, Metformin Hydrochloride · Oral

Last checked: Nov 20, 2026Latest source record: Aug 11, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Dec 19, 2017

Approved uses

2

Original approval plus efficacy supplements

Registered trials

43

14 Phase 3, 5 recruiting

FAERS reports

82

29 serious, 4 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Metformin-associated lactic acidosis was characterized by elevated blood lactate levels (>5 mmol/Liter), anion gap acidosis (without evidence of ketonuria or ketonemia), an increased lactate/pyruvate ratio, and metformin plasma levels generally >5 mcg/mL [see Warnings and Precautions (5.1) ] . Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g., carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast,...

What it is approved for

From the label in effect Aug 11, 2026.

SEGLUROMET ® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. SEGLUROMET is a combination of ertugliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, and metformin, a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 ) Limitations of Use: Not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus. ( 1 ) Limitations of Use Not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus [see Warnings and Precautions (5.2) ].

Mechanism: SEGLUROMET SEGLUROMET combines two antihyperglycemic agents with complementary mechanisms of action to improve glycemic control in patients with type 2 diabetes mellitus: ertugliflozin, a SGLT2 inhibitor, and metformin hydrochloride, a member of the biguanide class. Ertugliflozin SGLT2 is the predominant transporter responsible for reabsorption of glucose from the glomerular filtrate back into the circulation. Ertugliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, ertugliflozin reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

4 products under this application
  • SEGLUROMET · ERTUGLIFLOZIN 2.5MG; METFORMIN HYDROCHLORIDE 500MG · TABLET, ORAL · Prescription
  • SEGLUROMET · ERTUGLIFLOZIN 7.5MG; METFORMIN HYDROCHLORIDE 1GM · TABLET, ORAL · Prescription
  • SEGLUROMET · ERTUGLIFLOZIN 2.5MG; METFORMIN HYDROCHLORIDE 1GM · TABLET, ORAL · Prescription
  • SEGLUROMET · ERTUGLIFLOZIN 7.5MG; METFORMIN HYDROCHLORIDE 500MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Ertugliflozin" as an intervention, any sponsor and status, largest first.

All 43 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • product dose omission issue11
  • no adverse event8
  • nausea7
  • diabetic ketoacidosis6
  • vomiting6
  • asthenia5
  • diarrhoea4
  • inability to afford medication4
  • blood glucose increased3
  • decreased appetite3
  • drug ineffective3
  • inappropriate schedule of product administration3

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20186
201924
202010
202115
202210
20236
20246
20253
20262

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Segluromet (Ertugliflozin/Metformin)

2024 spending

$1.1M

Beneficiaries

583

2,129 claims

Per beneficiary

$1,949

$5.60 per unit

View as table
YearSpending
2020$639,473
2021$838,925
2022$1,142,029
2023$1,266,291
2024$1,136,458

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 120 on PubMed

Sponsor: Merck & Co.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.